Inventor
Richard H. Weisbart
Inventor
Los Angeles, CA, US
Overview
Patents· 23 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes31%
C07KPeptides29%
G01NInvestigating or analysing materials by determining their chemical or physical properties13%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations10%
C12NMicroorganisms or enzymes8%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests6%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms3%
PatentTitleYear
10,961,301Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair202110,702,543Intranuclear protein transduction through a nucleoside salvage pathway202010,703,807Antibody-mediated transduction of heat shock proteins into living cells202010,683,363Targeting intracellular target-binding determinants with intracellular antibodies202010,383,945Methods for DNA-dependent targeting of a cell permeant antibody201910,238,742Cell penetrating nucleolytic antibody based cancer therapy201910,040,867Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations20189,732,146'Antibody-mediated transduction of heat shock proteins into living cells'20179,701,740'Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair'2017RE046211'Delivery system using MAB 3E10 and mutants and/or functional fragments thereof'20169,283,272'Targeting intracellular target-binding determinants with intracellular antibodies'20169,155,801'Amino acid sequences which enhance peptide conjugate solubility'20159,133,460'Methods for determining and inhibiting rheumatoid arthritis associated with the BRAF oncogene in a subject'20158,956,825'Intranuclear protein transduction through a nucleoside salvage pathway'20158,680,066'Methods for determining and inhibiting rheumatoid arthritis associated with the BRAF oncogene in a subject'20147,189,396'Delivery system using mAb 3E10 and mutants and/or functional fragments thereof'20076,232,444'Conserved anti-DNA antibody idiotype associated with nephritis in murine and human lupus'20016,200,565'Oral administration of immunoglobulins for treating autoimmune hearing loss'20016,090,380'Treatment of rheumatoid arthritis by oral administration of pooled human immunoglobulin'20005,252,461'Mixed immunoglobulins for detection of rheumatoid factors'19935,238,851'Mixed immunoglobulins for detection of rheumatoid factors'19935,034,316'In vitro human monoclonal IgG rheumatoid factor autoantibody'19914,812,397'MAB-anti-DNA related to nephritis'1989Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1989–2021Patents assigned to UNIV CALIFORNIA (8)· patent assignee history
1989–2021Based in Los Angeles, CA, US· patent location history
2007–2016Patents assigned to US DEPT VETERANS AFFAIRS (5)· patent assignee history
2014–2017Patents assigned to WEISBART RICHARD H (7)· patent assignee history
2014–2020Based in Sepulveda, CA, US· patent location history
2017–2020Patents assigned to US VETERANS AFFAIRS (5)· patent assignee history
2017–2021Patents assigned to UNIV YALE (4)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| UNIV CALIFORNIA | 8 | 1989–2021 |
| WEISBART RICHARD Hself | 7 | 2014–2017 |
| US DEPT VETERANS AFFAIRS | 5 | 2007–2016 |
| US VETERANS AFFAIRS | 5 | 2017–2020 |
| UNIV YALE | 4 | 2017–2021 |
Locations
| Location | Patents | Span |
|---|---|---|
| Los Angeles, California, US | 16 | 1989–2021 |
| Sepulveda, California, US | 7 | 2014–2020 |